|
KMID : 0578320210440050363
|
|
Molecules and Cells
2021 Volume.44 No. 5 p.363 ~ p.373
|
|
|
Clinical Perspectives to Overcome Acquired Resistance to Anti?Programmed Death-1 and Anti?Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
|
|
Lee Yong-Jun
Lee Jii-Bum
Ha Sang-Jun
Kim Hye-Ryun
|
|
|
Abstract
|
|
|
|
Immune checkpoint inhibitors have changed the paradigm of treatment options for non-small cell lung cancer (NSCLC). Monoclonal antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have gained wide attention for their application, which has been shown to result in prolonged survival. Nevertheless, only a limited subset of patients show partial or complete response to PD-1 therapy, and patients who show a response eventually develop resistance to immunotherapy. This article aims to provide an overview of the mechanisms of acquired resistance to anti?PD-1/PD-L1 therapy from the perspective of tumor cells and the surrounding microenvironment. In addition, we address the potential therapeutic targets and ongoing clinical trials, focusing mainly on NSCLC.
|
|
|
KEYWORD
|
|
|
acquired resistance, immune checkpoint inhibitors, non-small cell lung cancer, programmed death-1, programmed death ligand-1
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|